Corporate News

Medios AG invests in significant expansion of production capacities for personalised medicines

- Speciality Pharma company buys property including building in Berlin-Charlottenburg

- Construction of new manufacturing facility planned, with latest technology and higher productivity

- Production capacity can be increased fivefold by 2020

Berlin, 29 March 2017 - Medios AG, a competence partner and solution provider in the Speciality Pharma segment, has today acquired a property for significantly expanding the production capacities of its subsidiary Medios Manufaktur GmbH and merging the activities of the Medios Group on one site. The property is situated in an industrial estate in Berlin-Charlottenburg. It comprises 3,195 square metres of land and an office building. Including the expansion of production capacities and the construction of another building, total investment on this property will come to around EUR 11 million.

Manfred Schneider, Chief Executive Officer of Medios AG: "The property is perfectly suited for implementing our growth strategy. It has enough space to merge all the companies of the Medios Group on one site in the medium term. That will enable us to optimise our business processes, make better use of synergies and reduce costs. The location is also future-proof, because we can successively expand the production capacities of Medios Manufaktur there significantly, depending on requirements. Capacities for manufacturing individual patient infusions can be increased fivefold by 2020, for example."

Planning has already begun on expanding production capacities and the construction work is due to be completed by late 2018. The office building on the purchased property has a total area of approx. 2,000 square metres and is to be used for the business operations of Medios Manufaktur GmbH. Another building with up to 3,000 square metres of floor space is also to be built to accommodate Medios AG, Medios Pharma GmbH and Medios Digital GmbH.

The funds for the acquisition of the property and the necessary alterations come partly from the net proceeds of the cash capital increase carried out by Medios AG in December 2016. As announced in the securities prospectus in November 2016, the intention was to invest up to EUR 11 million to purchase a property, erect a building and equip the laboratories and offices.

For the ongoing operations, Medios AG and its subsidiaries Medios Pharma GmbH, Medios Manufaktur GmbH and Medios Digital GmbH are currently renting five offices at different locations in Berlin. The central location of the future group headquarters will continue to ensure that all customers and partners in Berlin are supplied on time and at short notice.

About Medios AG
Medios AG positions itself - along with its sister companies Medios Pharma, Medios Manufaktur and Medios Digital - as a competence partner and solution provider for the Specialty Pharma segment. Medios AG interconnects individual actors within the market and turns them into co-operating partners. It is our goal to guarantee best possible pharmaceutical care for patients while providing our partners and clients with integrated solutions along the supply chain. Specialty Pharma medicine are pharmaceuticals for patients with rare and chronic diseases such as certain cancer types and autoimmune / infectious diseases, which are time-consuming and cost-intensive to cure.

Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Herrengraben 1
20459 Hamburg
Telefon: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.